Canada markets open in 2 hours 35 minutes

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2900-0.0300 (-1.29%)
At close: 04:00PM EDT
2.2200 -0.07 (-3.06%)
Pre-Market: 05:02AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.3200
Open2.3600
Bid0.0000 x 800
Ask0.0000 x 1200
Day's Range2.2500 - 2.3600
52 Week Range2.1200 - 4.5790
Volume54,066
Avg. Volume125,579
Market Cap48.473M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-0.9800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.15
  • GlobeNewswire

    IBN Coverage Initiated for Longeveron Inc.

    LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announced it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. Longeveron’s research and therapies a

  • GlobeNewswire

    Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

    MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome

  • GlobeNewswire

    Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference

    MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 ,